Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
RS Oncology LLC
Massachusetts General Hospital
Amphia Hospital
Western Sydney Local Health District
University of Turin, Italy
Ascentage Pharma Group Inc.
Infinity Pharmaceuticals, Inc.
Sohag University
Hospices Civils de Lyon
University of Maryland, Baltimore
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Shenzhen BinDeBio Ltd.
Royal Brompton & Harefield NHS Foundation Trust
Bay Area Gynecology Oncology
NHS Greater Glasgow and Clyde
Ain Shams University
Erasmus Medical Center
Brigham and Women's Hospital
Wales Cancer Trials Unit
British Columbia Cancer Agency
Columbia University
Institute of Oncology Ljubljana
King's College London
Wuhan University
Taxolog Inc.
Gruppo Italiano MEsotelioma